ArticlePloS one2012

Cost-effectiveness of adding cetuximab to platinum-based chemotherapy for first-line treatment of recurrent or metastatic head and neck cancer.

Malek B Hannouf et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.